The pharmaceutical and biotechnology sector has performed well in recent years, primarily by virtue of attractive fundamentals.
Stock by stock performance has, of course, been mixed, but in general, the sector has shrugged off concerns about patent cliffs, generic competition, and a lack of new drugs coming through clinical pipelines,...
Uptick in investor sentiment
Converting £1.9bn European Special Sits fund
According to Cicero report
Newly created role